MX352796B - Proteina de fusion anticancerigena. - Google Patents
Proteina de fusion anticancerigena.Info
- Publication number
- MX352796B MX352796B MX2014008028A MX2014008028A MX352796B MX 352796 B MX352796 B MX 352796B MX 2014008028 A MX2014008028 A MX 2014008028A MX 2014008028 A MX2014008028 A MX 2014008028A MX 352796 B MX352796 B MX 352796B
- Authority
- MX
- Mexico
- Prior art keywords
- domain
- fusion protein
- sequence
- terminus
- amino acid
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04003—Phospholipase C (3.1.4.3)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Insects & Arthropods (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL397595A PL223487B1 (pl) | 2011-12-28 | 2011-12-28 | Przeciwnowotworowe białko fuzyjne |
| PCT/IB2012/057657 WO2013098755A2 (en) | 2011-12-28 | 2012-12-22 | Anticancer fusion protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014008028A MX2014008028A (es) | 2014-08-21 |
| MX352796B true MX352796B (es) | 2017-12-07 |
Family
ID=47716118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014008028A MX352796B (es) | 2011-12-28 | 2012-12-22 | Proteina de fusion anticancerigena. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20140377216A1 (enExample) |
| EP (1) | EP2797950B1 (enExample) |
| JP (1) | JP6324905B2 (enExample) |
| KR (1) | KR20140110017A (enExample) |
| CN (1) | CN103987728B (enExample) |
| AU (1) | AU2012360086B2 (enExample) |
| BR (1) | BR112014015922A2 (enExample) |
| CA (1) | CA2859494A1 (enExample) |
| CY (1) | CY1120055T1 (enExample) |
| DK (1) | DK2797950T3 (enExample) |
| EA (1) | EA201491277A1 (enExample) |
| ES (1) | ES2655828T3 (enExample) |
| HR (1) | HRP20180012T1 (enExample) |
| HU (1) | HUE035794T2 (enExample) |
| IL (1) | IL232834A (enExample) |
| LT (1) | LT2797950T (enExample) |
| MX (1) | MX352796B (enExample) |
| NO (1) | NO2797950T3 (enExample) |
| PH (1) | PH12014501363A1 (enExample) |
| PL (2) | PL223487B1 (enExample) |
| PT (1) | PT2797950T (enExample) |
| RS (1) | RS56758B1 (enExample) |
| SG (1) | SG11201403282QA (enExample) |
| SI (1) | SI2797950T1 (enExample) |
| SM (1) | SMT201800026T1 (enExample) |
| UA (1) | UA115436C2 (enExample) |
| WO (1) | WO2013098755A2 (enExample) |
| ZA (1) | ZA201405460B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014141094A1 (en) | 2013-03-14 | 2014-09-18 | Adamed Sp. Z O.O. | Anticancer conjugate |
| GB201406705D0 (en) | 2014-04-15 | 2014-05-28 | Univ Liverpool | Fusion proteins,polynucleotides,expression vectors, and their uses |
| US10428132B2 (en) | 2015-02-11 | 2019-10-01 | West China Hospital, Sichuan University | Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof |
| CN107216385A (zh) * | 2017-05-19 | 2017-09-29 | 何向锋 | 肿瘤特异性重组水蛭素及其制备方法和用途 |
| CN109400711B (zh) * | 2017-05-31 | 2022-02-08 | 四川大学华西医院 | 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途 |
| WO2019067740A1 (en) * | 2017-09-27 | 2019-04-04 | Emory University | FUSION PROTEINS COMPRISING CANCER TOXIN AND MARKER, NANOPARTICLES AND USES THEREOF |
| CN111909275A (zh) * | 2019-05-08 | 2020-11-10 | 上海大学 | 延长多肽药物循环半衰期的靶向载药体系及其构建方法 |
| CN110669146B (zh) * | 2019-10-24 | 2023-05-23 | 常州大学 | 一种可特异性阻断衔接蛋白Nck的结合位点用于预防肠道EPEC感染的活性肽 |
| KR102659285B1 (ko) * | 2020-08-11 | 2024-04-22 | 경북대학교 산학협력단 | 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도 |
| CN114031673B (zh) * | 2021-12-22 | 2023-09-22 | 杭州长龄生物科技有限公司 | 一种多肽及其制备方法 |
| CN114605517B (zh) * | 2022-05-12 | 2022-09-27 | 广东海洋大学 | 一种具有广谱抗癌作用的多肽lxp-7及其应用 |
| CN116063389B (zh) * | 2022-08-23 | 2023-07-07 | 广州医科大学 | 递送核酸药物的多肽载体、治疗肿瘤的核酸药物及其制备方法 |
| EP4631515A1 (en) * | 2024-04-12 | 2025-10-15 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Antitumor parasporin-2 derived toxins |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0753071A1 (en) | 1993-04-28 | 1997-01-15 | Worcester Foundation For Experimental Biology | Cell-targeted lytic pore-forming agents |
| CA2225378C (en) | 1995-06-29 | 2012-04-17 | Immunex Corporation | Cytokine that induces apoptosis |
| US6284236B1 (en) * | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| CA2544473C (en) | 2003-11-03 | 2013-08-13 | Beijing Sunbio Biotech Co., Ltd. | A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof |
| CN1256347C (zh) * | 2003-12-10 | 2006-05-17 | 中国人民解放军第二军医大学 | 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途 |
| BRPI0615997A8 (pt) | 2005-08-16 | 2018-05-22 | Genentech Inc | método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção |
| WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| GB0723059D0 (en) | 2007-11-23 | 2008-01-02 | Nat Univ Ireland | Improved cytokine design |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| WO2009094634A1 (en) * | 2008-01-24 | 2009-07-30 | Esperance Pharmaceuticals | Lytic domain fusion constructs and methods of making and using same |
| WO2009140469A2 (en) | 2008-05-14 | 2009-11-19 | Genentech, Inc. | Methods of using apo2l/trail to treat cancer |
-
2011
- 2011-12-28 PL PL397595A patent/PL223487B1/pl unknown
-
2012
- 2012-12-22 KR KR1020147021158A patent/KR20140110017A/ko not_active Ceased
- 2012-12-22 SI SI201231178T patent/SI2797950T1/en unknown
- 2012-12-22 US US14/367,681 patent/US20140377216A1/en not_active Abandoned
- 2012-12-22 PL PL12824731T patent/PL2797950T3/pl unknown
- 2012-12-22 HR HRP20180012TT patent/HRP20180012T1/hr unknown
- 2012-12-22 MX MX2014008028A patent/MX352796B/es active IP Right Grant
- 2012-12-22 CN CN201280060782.7A patent/CN103987728B/zh not_active Expired - Fee Related
- 2012-12-22 DK DK12824731.9T patent/DK2797950T3/en active
- 2012-12-22 ES ES12824731.9T patent/ES2655828T3/es active Active
- 2012-12-22 HU HUE12824731A patent/HUE035794T2/en unknown
- 2012-12-22 EA EA201491277A patent/EA201491277A1/ru unknown
- 2012-12-22 EP EP12824731.9A patent/EP2797950B1/en active Active
- 2012-12-22 SM SM20180026T patent/SMT201800026T1/it unknown
- 2012-12-22 AU AU2012360086A patent/AU2012360086B2/en not_active Ceased
- 2012-12-22 JP JP2014549601A patent/JP6324905B2/ja active Active
- 2012-12-22 UA UAA201408554A patent/UA115436C2/uk unknown
- 2012-12-22 LT LTEP12824731.9T patent/LT2797950T/lt unknown
- 2012-12-22 SG SG11201403282QA patent/SG11201403282QA/en unknown
- 2012-12-22 PT PT128247319T patent/PT2797950T/pt unknown
- 2012-12-22 NO NO12824731A patent/NO2797950T3/no unknown
- 2012-12-22 WO PCT/IB2012/057657 patent/WO2013098755A2/en not_active Ceased
- 2012-12-22 CA CA2859494A patent/CA2859494A1/en not_active Abandoned
- 2012-12-22 RS RS20180036A patent/RS56758B1/sr unknown
- 2012-12-22 BR BR112014015922-0A patent/BR112014015922A2/pt not_active IP Right Cessation
-
2014
- 2014-05-27 IL IL232834A patent/IL232834A/en active IP Right Grant
- 2014-06-16 PH PH12014501363A patent/PH12014501363A1/en unknown
- 2014-07-24 ZA ZA2014/05460A patent/ZA201405460B/en unknown
-
2018
- 2018-01-16 CY CY20181100048T patent/CY1120055T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014008028A (es) | Proteina de fusion anticancerigena. | |
| PH12014501083A1 (en) | Anticancer fusion protein | |
| PH12013500715A1 (en) | Anticancer fusion protein | |
| PH12013500714A1 (en) | Anticancer fusion protein | |
| PH12013500050A1 (en) | Anticancer fusion protein | |
| PH12018502451A1 (en) | Brain delivery protein | |
| WO2013152351A3 (en) | Fusion polypeptides and methods of use thereof | |
| NZ603196A (en) | Methods of use of soluble cd24 for therapy of rheumatoid arthritis | |
| NZ629843A (en) | Identification of channelrhodopsin-2 (chop2) mutations and methods of use | |
| MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2023010178A (es) | Conjugados de anticuerpo farmaco anti-cd70. | |
| MX2020010399A (es) | 3-epimerasa. | |
| WO2016004906A3 (zh) | 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用 | |
| PH12013501970A1 (en) | Anticancer fusion protein | |
| MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
| WO2011135222A3 (fr) | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles | |
| EP4361634A3 (en) | Methods for treating and monitoring the status of cancer | |
| WO2013109190A3 (en) | Cho-gmt recombinant protein expression | |
| PH12014502198A1 (en) | Osteoprotegerin derived composition and use thereof | |
| AR079370A1 (es) | Uso de peptidos antimicrobianos para el tratamiento de infeccion urinaria/cistitis | |
| UA108911C2 (xx) | Протираковий злитий протеїн | |
| WO2011150897A3 (es) | Método para la terapia del cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |